ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ANIK / insiders
INFU (77) TMCI (36) OSUR (31) PROF (40) ⌘ Pro Terminal β†’

Anika Therapeutics Inc. (ANIK) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$19.41 -7.35% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.12

Anika Therapeutics Inc. (ANIK) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ β€’ SELL / AVOID Cap $280.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANIK Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ANIK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $19.41 (-7.35% 1D, market cap $280.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, ANIK ranks #235 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ANIK compare to INFU and TMCI in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and TMCI (Treace Medical Concepts Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.4%, cap $288.1M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANIK?
β–Ό

Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.12 (-1.51%)🧬 Dilution Drag (+1.36% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 3.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY β€’ 50.6% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510053
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ Β· Rk D+
Cash (12)Whales (12)SEC (11)Macro (11)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-2.3% Base Target
$24 Bull$19 Base$15 Bear
πŸ“¬ FREE ANIK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ANIK)Realized 20D OHLCV Swing Band: Β±7.9%
Deterministic 5-Pillar Attribution (53/100 Composite)
πŸ” WHY ANIK SCORES 53/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($4.4M FCF) & 56.6% Gross Margin

β–² #2 Bullish Driver: Whale & Options Positioning+12/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±7.9% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Dilution Drag (+1.36% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
61
Grade C$20.53-0.4% Next Q
Q2 (-2Q)
58
Grade C$20.44+4.5% Next Q
Q3 (-1Q)
56
Grade C$21.35-9.1% Next Q
Current
53
Grade D+$19.41-0.9% Hist 90D Ξ±
Trajectory: C (61) β†’ D+ (53)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ANIK Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ANIK currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.66) and Max Pain ($20.38) forces dealer call-delta covering toward $24.02.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANIKβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œANIK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

ANIK Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ANIK)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ANIK. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANIK)

  • βœ“Walkthrough of ANIK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ANIK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +33.40%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $21.79H $21.79L $19.41C $19.41VOL 66.7K
RES: $21.80SUP: $19.40SMA50: $20.66SMA200: $16.19
$23.73$20.20$16.67$13.14$9.61RES $21.80SUP $19.40$19.412026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANIK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ANIK Butterfly Map β†’ + Track ANIK β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ANIK today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ANIK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANIK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIK)

Health Care Rank #235 of 1015 βš”οΈ INFU vs ANIK Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ANIK vs. INFU, TMCI, OSUR, PROF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Anika Therapeutics Inc. (ANIK) ranks #235 by composite RQD confidence (53/100, grade D+) and #523 by equity capitalization ($280.4M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with ANIK at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANIK ACTIVE
Anika Therapeutics Inc.
D+ 53/100 β€” 56.6% -10.2% -7.35% $280.4M Benchmark Subject
INFU
InfuSystems Holdings Inc.
B+ 77/100 43.4x 56.0% 12.8% -1.63% $280.2M /infu-vs-anik β†’
TMCI
Treace Medical Concepts Inc.
D- 36/100 β€” 79.8% -32.4% -3.61% $288.1M /tmci-vs-anik β†’
OSUR
OraSure Technologies Inc.
E 31/100 β€” 41.9% -35.0% -12.31% $271.7M /osur-vs-anik β†’
PROF
Profound Medical Corp.
D- 40/100 β€” 70.8% -35.0% +2.44% $240.0M /prof-vs-anik β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000898437 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anika Therapeutics Inc. (ANIK) reported GAAP revenue of $112.8M (-5.9% vs. FY2024 revenue of $119.9M , and -6.6% cumulative change since FY2023) , GAAP net income of -$11.0M, operating cash flow of $11.2M, and free cash flow of $4.4M (+287.1% YoY). On the balance sheet, ANIK closed FY2025 with $190.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $112.8M -$11.0M $11.2M $4.4M $190.3M β€”
FY2024 (FY) 2024-12-31 $119.9M -$56.0M $5.4M -$2.3M $202.7M β€”
FY2023 (FY) 2023-12-31 $120.8M -$83.0M -$1.8M -$1.8M β€” β€”

3. ANIK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANIK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $19.41 (-7.35% 1D, market cap $280.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, ANIK ranks #235 in composite RQD confidence.

How does ANIK compare to INFU and TMCI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and TMCI (Treace Medical Concepts Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.4%, cap $288.1M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANIK?

Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANIK trading relative to its 50-day, 200-day, and 52-week technical levels?

ANIK last traded at $19.41 (-7.35% on volume of 95,334 shares), positioning the stock -6.05% below its 50-day simple moving average ($20.66) and +19.89% above its 200-day simple moving average ($16.19). Across its 52-week range of $9.01 to $22.88, ANIK sits at the 75.0% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±7.9% ($17.88 to $20.94).

Direct Sub-Reports: ANIK RQD Cockpit ANIK 12M Forecast ANIK Earnings & Move ANIK Dividends & DRIP ANIK Insiders & 13F ANIK Whale Options ANIK Profit Sankey ANIK News & Why
ROARABLE RATING BRIEF β€’ RQD 53/100 (D+) βœ“ SEC XBRL & RQD VERIFIED

ANIK β€” Anika Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Anika Therapeutics Inc. (ANIK) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $19.41 (-7.35% 1D, market capitalization $280.4M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of -10.2%, gross margin of 56.6%, operating margin of -9.8%, and free cash flow yield of 1.50%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Anika Therapeutics Inc. (ANIK) is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry, with a market capitalization of $0.3B.) The Market Data section reports a gross margin of 56.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Anika Therapeutics Inc. (ANIK) reported $112.8M in annual revenue (up from $119.9M in FY2024, -5.9% YoY) and -$11.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($120.8M revenue, -$83.0M net income) through FY2025, ANIK scaled operating cash flow to $11.2M and free cash flow to $4.4M, backed by $190.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D+ β€’ RQD 53/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.50% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $9.01 – $22.88 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -9.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the absence of mapped links means this dataset cannot identify 2nd-order bottlenecks or ripple effects.

  • Key Question #1: Can ANIK sustain or expand its -9.8% operating margin and -10.2% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $112.8M and free cash flow of $4.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ANIK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ANIK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Anika Therapeutics Inc. (ANIK) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ANIK Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANIK Bull vs. Bear Conversation Board β€” What's Your Call at $19.41?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANIK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ANIK:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER β€’ Verified $100K Arena Trader πŸ‚ BULLISH 🎯 Target: $24.51 (+17.0%)
πŸ“Œ Pinned Debate

The balance sheet and institutional flow pillars (Altman Z 2.5, Piotroski F 6/9, Whale 13F 14/20) suggest a financially stable base wit

The street is overcomplicating Anika Therapeutics Inc. (ANIK). The balance sheet and institutional flow pillars (Altman Z 2.5, Piotroski F 6/9, Whale 13F 14/20) suggest a financially stable base with some institutional support.. With an RQD score of 53/100 (D+) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $22.63.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” ANIK's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $17.81 (-15.0%)
Spot @ $20.95

Negative ROIC of -10.2%, a 1.5% FCF yield, and a 7/20 insider conviction score point to weak returns on capital and little insider conf

Negative ROIC of -10.2%, a 1.5% FCF yield, and a 7/20 insider conviction score point to weak returns on capital and little insider confidence.. Look at the math on ANIK: paying current EV/EBITDA multiples for -10.2% ROIC and -9.8% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $18.44 before getting long.

LIVE TAPE